Clinical Trial

Outpatient Epcoritamab in Large B-cell Lymphoma

Name: Outpatient Epcoritamab in Large B-cell Lymphoma — clinical trial record (NCT06811272)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.

Protocol Amendment History 3 changes

critical Primary endpoint(s) modified 2026-08-14

notable Enrollment increased: 30 -> 40 participants 2026-08-14

minor Trial arms changed: 1 -> 2 2026-08-14

Trial Details

NCT Number	NCT06811272
Lead Sponsor	Massachusetts General Hospital Collaborators: Genmab
Conditions	Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Enrollment	40 participants
Start Date	2025-06-05
Primary Completion	2026-10-01 (estimated)
Study Completion	2028-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-13